Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

Actelion awards grants to 2011 ENTELLIGENCE young investigators for research in pulmonary arterial hypertension

Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the ENTELLIGENCE program supported by Actelion. The announcement was made at an awards luncheon, during which the recipients of the 2011 awards gave an overview of their proposed work.

14 Jun 2011

Severe sleep apnea increases risk of gestational diabetes and preterm birth in pregnant women

Sleep apnea is associated with an increased risk of adverse pregnancy outcomes, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS).

13 Jun 2011

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, the retail health care division of CVS Caremark, and OhioHealth, a nationally recognized not-for-profit, charitable health care organization based in Columbus, Ohio, have entered into a clinical affiliation that will enhance the high quality, affordable health care services they provide in central Ohio.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Adaptation of fat cell membranes to obesity may play a key role in early stages of inflammatory disorders

The mechanisms by which obesity leads towards metabolic co-morbidities, such as diabetes mellitus, are poorly understood and of great public health interest. A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that adaptation of fat cell membranes to obesity may play a key role in the early stages of inflammatory disorders.

10 Jun 2011

DASH diet comes out on top

DASH diet, often recommended to help adults lower their blood pressure has ranked over more popular options in a ranking of 20 diets by U.S. News & World Report. The DASH diet, the magazine concluded, was the best overall. Government approved DASH standing for Dietary Approaches to Stop Hypertension was chosen by the magazine’s panel of nutrition experts among other things, being nutritious, easy to follow and protecting against heart disease and perhaps diabetes.

8 Jun 2011

Einstein health expert plays an important role in development of U.S. News 'Best Diets' rankings

Yasmin Mossavar-Rahmani, Ph.D., R.D. of Albert Einstein College of Medicine of Yeshiva University played an important role in the development of the "Best Diets" rankings, which U.S. News released today.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.

8 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Study to determine how vitamin D affects cardiac structure, functions in blacks with hypertension

A Wayne State University School of Medicine physician researcher has received a $1.9 million National Institutes of Health grant to study the role of vitamin D in halting and reducing subclinical cardiac damage in African-Americans suffering from high blood pressure.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Angiotensin receptor blockers do not increase risk of cancer: FDA

The U.S. Food and Drug Administration today announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications.

3 Jun 2011

KGI scientists identify new gene regulator that keeps hearts healthy even under intense exercise

Providing a medical explanation for why exercise is good for the heart, a team of scientists from Brazil pursuing a study that started in Dr. Ian Phillips' lab at Keck Graduate Institute (KGI) has discovered a new gene regulator called MicroRNA 29 that keeps hearts healthy even under intense exercise.

3 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

Hypertension (High Blood Pressure) News and Research

Further Reading

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Actelion awards grants to 2011 ENTELLIGENCE young investigators for research in pulmonary arterial hypertension

Severe sleep apnea increases risk of gestational diabetes and preterm birth in pregnant women

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Adaptation of fat cell membranes to obesity may play a key role in early stages of inflammatory disorders

DASH diet comes out on top

Einstein health expert plays an important role in development of U.S. News 'Best Diets' rankings

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Study to determine how vitamin D affects cardiac structure, functions in blacks with hypertension

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Angiotensin receptor blockers do not increase risk of cancer: FDA

KGI scientists identify new gene regulator that keeps hearts healthy even under intense exercise

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News